Ascendis Pharma A/S - ASND Company Short-Term Debt

Public company logo of Ascendis Pharma A/S (ASND)

Short-term debt volume demonstrates the financial stability of Ascendis Pharma A/S (ASND), whose scalability is based on the TransCon platform to reduce R&D costs. Ian Knudsen's team is successfully commercializing developments, confirming market confidence. Strong European scientific human capital is supported by academic freedom. The value of 0.05 serves as the final marker for the company's current liability level.

ASND (Ascendis Pharma AS) Company Short-Term Debts history from 07/04/2022 to 10/28/2026

Summary analytical data breakdowns for Ascendis (ASND)

- price and consensus price forecast:
Price Chart Ascendis Pharma|ASND - Fair Value Consensus
- market capitalization data:
Market Value Ascendis Pharma A/S|ASND - Real Price to Acquire Entire Company
- book capitalization data:
Book Value per Share Ascendis Pharma|ASND - Book Capitalization|Market Cap to Net Assets Ratio ascendispharma.com|ASND - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Ascendis Pharma A/S|ASND - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Ascendis Pharma A/S|ASND - Company Cumulative Debt|Debt to Book Value Ascendis Pharma A/S|ASND - Amount of Long-Term Liabilities|Company Short-Term Debts Ascendis Pharma
Initial company analysis:ASND (Ascendis Pharma)
Flagship merchandise of Ascendis

Unique drug delivery technology and patent protection allow Ascendis Pharma A/S (ASND) to independently determine drug pricing to ensure return on investment. High business margins directly impact the company's ability to service current liabilities. This metric aggregates all obligations with a maturity of up to one year. An increase in this volume signals a risk of a liquidity gap. By analyzing short-term financial debts with a maturity of up to one year, an investor assesses the issuer's short-term liquidity.

Competitors of Ascendis Pharma A/S (ASND)

Company Short-Term Debt Madrigal Pharmaceuticals, Inc. (MDGL)|CORT: Company Short-Term Loans and Borrowings|RYTM (Rhythm Pharmaceuticals Inc) - Company Short-Term Debt|Akero Corp (AKRO) - Company Current Liabilities|MTSR (Metsera Inc) - Company Short-Term Debts|Company Short-Term Debts moonlaketx.com (MLTX)|Crinetics (CRNX) - Company Current Liabilities|Company Short-Term Loans and Borrowings NAMS (NewAmsterdam Pharma Company)|Soleno - Company Short-Term Debt|Company Current Liabilities Amicus Corp FOLD|ETNB (89bio, Inc.) - Company Short-Term Debts|agios.com (AGIO) - Short-Term Debt|GPCR - Company Current Liabilities|MiMedx Group Inc (MDXG) - Amount of Current Liabilities|RZLT (Rezolute Corp) - Company Short-Term Debts|Company Short-Term Debts Lexicon Corp|Company Short-Term Debts MBX Biosciences Inc (MBX)|Company Short-Term Debt ALT (altimmune.com)|AARD: Company Short-Term Debt|Sagimet Biosciences, Inc. - Short-Term Debt|BIOA - Company Short-Term Debt|BMEA - Company Short-Term Debt|quincetx.com - Company Short-Term Debts|GUTS (fractyl.com) - Short-Term Debt Volume|VTVT: Company Short-Term Debt|Short-Term Debt Volume ATPC|Company Short-Term Debt PLUR (Pluri Inc.)|Company Current Liabilities synlogictx.com (SYBX)|Company Short-Term Debts LPCN (Lipocine Inc.)|Matinas BioPharma Holdings, Inc. - Company Short-Term Debts|Company Short-Term Debt SPRB (Spruce Biosciences)|GLTO - Short-Term Debt Volume|CTCX (Carmell Corp) - Company Short-Term Debts|Lumos Therapeutics (LUMO) - Company Current Liabilities|Company Short-Term Debts ONVO (Organovo Holdings, Inc.)|Short-Term Debt RDUS